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Abstract
Purpose During the time of breastfeeding, a third of all women contract (or: fall ill in) mastitis—the leading cause of pre-
cocious weaning. Recent studies indicate that probiotics intake may prevent mastitis by altering the breast’s bacterial flora. 
The aim of this study was to examine whether probiotic milk intake during pregnancy is associated with less breastfeeding 
complications and longer breastfeeding duration.
Methods This study included 57,134 women, with live singleton term births, participating in the Norwegian Mother and 
Child Cohort Study. Probiotic milk intake during the first half of pregnancy was self-reported in a validated food frequency 
questionnaire at gestational week 22. At 6 month postpartum, women reported complications, including mastitis, and dura-
tion and exclusivity of breastfeeding. The association between probiotic milk intake and breastfeeding complications and 
duration was studied by adjusted logistic regression models.
Results Probiotic milk intake was associated with increased risk for mastitis [adjusted odds ratio (aOR) 1.09, 95% confidence 
interval (CI) 1.02–1.16] and for any breastfeeding problems during the first month (aOR 1.19, 95% CI 1.10–1.21). However, 
cessation of predominant (aOR 0.95, 95% CI 0.91–0.96) or any (aOR 0.79, 95% CI 0.75–0.84) breastfeeding earlier than at 
4 months was less frequent in probiotic milk consumers than in non-consumers.
Conclusions Even though probiotic milk intake during the first half of pregnancy was statistically associated with increased 
risk for breastfeeding complications, including mastitis, the association is probably not causal. Probiotics intake was namely 
associated with longer breastfeeding duration and there was indication of socioeconomic confounding. Further studies, i.e., 
large randomized-controlled trials, are needed to understand the association between probiotic intake and breastfeeding 
complications.
Keywords Probiotics · Probiotic milk intake · Cessation of breastfeeding · Mastitis · Breastfeeding complications · The 
Norwegian Mother and Child Cohort Study
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Background
Lactational mastitis is defined as an inflammatory process 
of the mammary gland, characterized by pain in the breast 
in conjunction with flu-like symptoms during breastfeeding. 
The World Health Organization (WHO) review on lactational 
mastitis reports an incidence ranging between 2.6% and 33% 
[1]. While WHO recommends 6 months of exclusive breast-
feeding, lactational mastitis is the leading cause of unplanned 
precocious weaning [1–3]. It causes substantial suffering for 
the mother and often disturbs the sensitive period of bonding 
between mother and newborn.
While mastitis previously was considered the consequence 
of a bacterial infection, new evidence suggests that breast 
health is instead determined by a balance between different 
microbiota in the breast tissue, as well as by the state of the 
host’s immune system [4, 5]. While antibiotics have been the 
traditional treatment approach, four recent randomized-con-
trolled trials (RCT) from Spain presented promising results 
with treatment (n = 352 [6], n = 108 [7]) or prophylactic intake 
(n = 108 [8], n = 625 [9]) of certain probiotic strains namely 
Lactobacillus (L.) salivarius, L. gasseri, and/or L. fermentum.
Several mechanisms for improvement of breast flora by pro-
biotics have been described, e.g., local competitive exclusion 
[10], production of antimicrobials [11], normalization of breast 
tissue permeability [12], and increase of immunoglobulin A in 
breast milk, which may limit the bacteria’s ability to damage 
mammary epithelium [13].
Today, probiotics are part of many milk products commonly 
purchased and widely consumed by the general population, 
including pregnant women. Our group has previously reported 
that free-market probiotic milk intake during pregnancy con-
taining Lactobacillus acidophilus La-5 (La-5), Bifidobacte-
rium lactis Bb12 (Bb12), and Lactobacillus rhamnosus GG 
(LGG) is associated with decreased risk for preterm delivery 
[14] and preeclampsia [15, 16]. To our knowledge, no pre-
vious studies have investigated the association between free-
market probiotic milk intake and breastfeeding complications 
and duration. The Norwegian Mother and Child Cohort Study 
(MoBa) has compiled detailed information on maternal probi-
otic milk intake during pregnancy, comprehensive information 
on breastfeeding, as well as general information on health and 
lifestyle [17]. It is thus a unique source for studying a possible 
preventive effect of probiotic milk intake during pregnancy 
on breastfeeding complications and duration in a population-
based cohort.
Objective
We hypothesized that free-market probiotic milk intake dur-
ing pregnancy prevents breastfeeding complications and thus 
promotes longer breastfeeding by stabilizing healthy breast 
flora. The aim of this study was to evaluate whether intake 
of probiotic milk products during pregnancy is associated 
with less breastfeeding complications, i.e., mastitis, medica-
tion for mastitis, sore nipples or other problems, or associ-
ated with longer breastfeeding duration (no cessation of any 
or predominant breastfeeding before 4 months).
Materials and methods
Study population
The MoBa is a prospective, population-based pregnancy 
cohort study conducted by the Norwegian Institute of Pub-
lic Health [17]. Participants were recruited from all over 
Norway from 1999 to 2008, and 41% of invited women 
consented to participate. Follow-up is conducted by ques-
tionnaires at regular intervals and by linkage to pregnancy 
and birth records in the Norwegian Medical Birth Register 
(NMBR) [18]. All questionnaires (Q) are available on the 
website of the Norwegian Institute of Public Health [19].
This study is based on version 10 of the quality-assured 
data files released for research in 2017.
Inclusion and exclusion criteria
Out of 114,240 births registered in MoBa, all singleton 
pregnancies with live births after gestational week 37 + 0 
were included in the study. Women had to have filled in 
questionnaires Q1 on general health and lifestyle, Q2 on 
dietary habits during pregnancy, and Q4 on follow-up 
6 month postpartum. As a quality measure of Q2, a food 
frequency questionnaire (FFQ), only women reporting an 
energy intake between 4.5 and 20 megajoules (MJ) daily 
were included. Mothers with reported autoimmune disease 
or cancer were excluded, as were babies born with serious 
malformations. Only the first pregnancy enrolled in MoBa 
was included in the analyses, to avoid repeated assessments 
of the same mother. After exclusion of women who did not 
initiate breastfeeding, 57,134 mother–baby pairs remained 
(see Fig. 1).
Exposure
Maternal probiotic milk intake during the first half of preg-
nancy was self-reported in the MoBa FFQ, a semi-quan-
titative questionnaire designed to record dietary habits. 
FoodCalc [20] and the Norwegian Food Composition Table 
[21] were used to calculate food and nutrient intakes. A vali-
dation study of the FFQ showed that, relative to a dietary 
reference method and several biological markers, the MoBa 
FFQ produces a realistic estimate of habitual intake and is a 
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valid tool for ranking pregnant women according to high and 
low intakes of energy, nutrients, and food [22].
The FFQ asked specifically about intake frequency of two 
probiotics-containing dairy products produced by Tine SA, 
Oslo, Norway (Product A:  Biola®, containing La-5, Bb12 
and LGG; and product B:  Cultura®, containing La-5 and 
Bb12). Responses ranged from “never” to “8 or more times 
per day”, with a total of 11 response alternatives. One glass 
was specified as 250 ml. The bacteria count in these bever-
ages is indicated as a minimum of 2 × 108 CFU of LGG and 
Bb12 and 2 × 107 CFU of La-5 per 1 mL product A and a 
minimum of 2 × 108 CFU of Bb12 and 2 × 107 CFU of La-5 
per 1 mL product B. These products were the only widely 
consumed probiotic products available on the Norwegian 
market at the time of the study. The MoBa FFQ included 
questions about the use of dietary supplements and an open 
text field for reporting supplements other than those listed. 
Very few women (fewer than 0.5%) reported consumption 
of probiotic supplements, and intake of probiotics from sup-
plements was thus not considered in this study.
Probiotic milk intake from both sources combined was 
studied as a dichotomous variable (yes/no) as well as in ter-
tiles of probiotics intake (low, medium, and high).
Outcome
In Q4, administered 6 month postpartum, women were asked 
whether they had consulted a doctor, midwife, or health visi-
tor during the first month after delivery for breast-related 
problems, specified as “mastitis”, “sore nipples”, or “breast-
feeding problems”, and whether they had received “medica-
tion for mastitis”. In addition to these four variables, a com-
bined variable, “any breastfeeding problems”, was created.
Fig. 1  Flowchart showing 
selection of study participants 
from the Norwegian Mother and 
Child Cohort Study (MoBa)
Number of births included in 
MoBa version 10, 1999-2009:
n= 114,240
Excluded:
Multiple births n= 3,969
Stillborn n= 650
Not answered Q1 n= 10,747
Not term-born n= 4,729
Serious malformations n= 4,147
Autoimmune disease or cancer n= 1,882
Not answered Q2* n= 14,265
Not answered Q4 n= 8,178
Not irst enrollment n= 7,949
Total n= 57,724 mother-baby pairs eligible for 
the analysis:
Probiotic milk consumers n= 21,054
Non-consumers n= 36,670
Excluded:
Not initiated breastfeeding n= 590
among probiotic milk consumers n= 153
among non-consumers n= 437
Total n= 57,134 mother-child pairs eligible for 
the analysis:
Probiotic milk consumers n= 20,901
Non-consumers n= 36,233
* Referring to women who did not answer the second version of the MoBa FFQ introduced in 2002, answered 
the FFQ with more than four blank pages or with inappropriate energy intake as a quality measure.
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Furthermore, mothers reported the specifics of their babies’ 
nutrition, both during the first week of life, choosing between 
breast milk, sugar water, water, and different types of formula, 
and then monthly, choosing between breast milk and different 
types of formula. Two breastfeeding variables were created 
based on the WHO definitions [23]: “cessation of predomi-
nant breastfeeding before 4 months” and “cessation of any 
breastfeeding before 4 months”. “Exclusive breastfeeding” 
could only be reported for the first week of life, as the ques-
tionnaires did not specifically ask about ingestion of water, 
water-based drinks, and fruit juices later on. “Predominant 
breastfeeding” refers to infants either given only breast milk 
(exclusive breastfeeding) or breast milk and water-based 
drinks, but infants should not be fed with solid food, non-
human milk or formula. This group thus includes those who 
were breastfed exclusively during their first week of life. “Any 
breastfeeding” refers to infants either given only breast milk 
(exclusive breastfeeding), predominantly breastfed (see above) 
or partially breastfed, i.e., given solid food, formula, or non-
human milk in addition to breast milk [23].
Confounders
Confounders were selected a priori. Maternal age was reg-
istered in the NMBR and used as a continuous variable. 
The following variables were self-reported in Q1: mater-
nal pre-pregnancy BMI was calculated based on reported 
height and pre-pregnancy weight and used as a categorical 
variable (< 18.5, 18.5–24.9, 25–29.9, > 30 kg/m2). Maternal 
education was categorized as < 13, 13–16, ≥ 16 years. Fam-
ily income was recorded as neither, one or both partners 
earning > 300,000 Norwegian Crowns (NOK)/year. Maternal 
smoking categories during pregnancy were never, occasion-
ally, and daily.
Based on the FFQ, daily fibre and energy intake were 
considered as continuous variables, while non-probiotic 
yoghurt and milk consumption were calculated as described 
above for probiotic milk intake.
Statistics
All analyses were performed using  IBM®  SPSS® Statistics 
version 25. Maternal characteristics, related to probiotic 
milk consumption, were analysed using Pearson’s chi-square 
test or the two-sided Fisher’s exact test. The Kruskal–Wallis 
test was used to study whether there was a statistical differ-
ence between the amounts of probiotic milk intake in the 
different maternal characteristic categories.
The associations between being a probiotic milk con-
sumer and breastfeeding complications and duration were 
studied by logistic regression analysis, unadjusted and 
adjusted for the confounders described above. Missing data 
were given a category of their own.
Sensitivity analyses were performed for the association 
between education and reported breastfeeding complica-
tions and duration, as well as between reported breastfeeding 
complications and breastfeeding duration.
Results
Probiotic milk intake in the study population
In our study population, 20,901 (36.6%) women were probi-
otic milk consumers. The median daily intake (interquartile 
range) among consumers was 54 ml/day (IQR 22–179).
Probiotic milk consumers had lower parity, although 
they were older. They had higher educational levels and 
income as well as more health-conscious behaviour, with 
higher fibre intake and less smoking than non-consumers 
(see Table 1).
Breastfeeding complications and duration
During the first month after delivery, a total of 4675 (8%) 
women in the study population contacted healthcare ser-
vices for mastitis and 3127 of these (6% of the total study 
population) received medication for the mastitis. Sore nip-
ples were reported by 3595 women (6%) and 3665 (6%) 
reported other breastfeeding problems. In total, 8788 women 
(15%) contacted healthcare services for any breastfeeding 
problems during the first month after delivery. Of the study 
population, 22,235 women (39%) ceased to predominantly 
breastfeed and 6567 women (11%) stopped any breastfeed-
ing before the baby reached the age of 4 months.
Probiotic milk intake was significantly associated with a 
higher incidence of breastfeeding complications (except for 
medication-treated mastitis), as well as a lower frequency 
of breastfeeding cessation before 4 months. Odds ratios 
(OR) became less pronounced after adjustment, but results 
remained significant (except for medication-treated mastitis, 
see Table 2).
However, there was no dose–response association 
between amount of probiotic milk intake either with breast-
feeding complications or duration (see Supplemental 
Table 1).
Sensitivity analyses were performed to better under-
stand the contradicting results of probiotic milk consumers 
having a higher incidence of breastfeeding complications, 
while also breastfeeding longer. First, the known association 
between breastfeeding complications and earlier cessation of 
breastfeeding was confirmed in this study population (see 
Table 3). Associations remained the same when studying the 
subgroups of probiotic milk consumers and non-consumers 
separately (data not shown).
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Table 1  Probiotic milk intake according to maternal characteristics, n = 57,134 women
Probiotic milk consumption p  value1 Mean (SD) daily probiotics intake among 
probiotics consumers, ml/day
p  value1
No, number (%) Yes, number (%)
All 36,233 (63.4) 20,901 (36.6) 123 (176)
Maternal age, years
 < 25 4190 (11.6) 1830 (8.8)  < 0.001 111 (168)  < 0.001
 25–29 12,278 (33.9) 7193 (34.4) 122 (174)
 30–34 15,478 (42.7) 9217 (44.1) 123 (175)
 ≥ 35 4287 (11.8) 2661 (12.7) 135 (185)
Pre-pregnancy BMI, kg/m2
 < 18.5 1025 (2.8) 582 (2.8)  < 0.001 129 (182) 0.01
 18.5–24.9 22,526 (62.2) 14,572 (69.7) 124 (174)
 25–29.9 8070 (22.3) 3961 (19.0) 122 (178)
 ≥ 30 3686 (10.2) 1339 (6.4) 113 (171)
 Missing 926 (2.6) 447 (2.1) 128 (204)
Parity
 0 17,061 (47.1) 11,987 (57.4)  < 0.001 126 (178)  < 0.001
 1 12,468 (34.4) 5957 (28.5) 117 (171)
 2 5398 (14.9) 2436 (11.7) 119 (173)
 ≥ 3 1278 (3.5) 506 (2.4) 135 (196)
 Missing 28 (0.1) 15 (0.1) 71 (125)
Maternal education, years
 < 13 12,192 (33.6) 4555 (21.8)  < 0.001 128 (186) 0.01
 13–16 15,250 (42.1) 9146 (43.8) 119 (174)
 ≥ 16 8032 (22.2) 6840 (32.7) 123 (168)
 Missing 759 (2.1) 360 (1.7) 144 (226)
Family income > 300,000 NOK
 Neither partner 10,678 (29.5) 4756 (22.8)  < 0.001 115 (168)  < 0.001
 One partner 15,308 (42.2) 8379 (40.1) 123 (172)
 Both partners 9287 (25.6) 7298 (34.9) 127 (181)
 Missing 960 (2.6) 468 (2.2) 138 (219)
Smoking in pregnancy
 Never 32,802 (90.5) 19,864 (95.0)  < 0.001 123 (176) 0.002
 Occasionally 1025 (2.8) 401 (1.9) 124 (166)
 Daily 2193 (6.1) 540 (2.6) 119 (177)
 Missing 213 (0.6) 96 (0.5) 109 (177)
Tertiles of daily energy intake
 1st 12,987 (35.8) 6044 (28.9)  < 0.001 85 (107)  < 0.001
 2nd 11,948 (33.0) 7111 (34.0) 112 (144)
 3rd 11,298 (31.2) 7746 (37.1) 161 (229)
Tertiles of daily fibre intake
 1st 13,388 (36.9) 5607 (26.8)  < 0.001 96 (146)  < 0.001
 2nd 12,068 (33.3) 7010 (33.5) 117 (168)
 3rd 10,777 (29.7) 8281 (39.6) 146 (196)
Tertiles of daily non-probiotic milk intake
 1st 11,610 (32.0) 6695 (32.0) 0.29 130 (187)  < 0.001
 2nd 13,121 (36.2) 7453 (35.7) 123 (161)
 3rd 11,502 (31.7) 6753 (32.3) 115 (179)
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Second, higher maternal education was associated with 
higher incidence of reported breastfeeding complications 
during the first month after delivery, as well as with longer 
duration of breastfeeding (see Supplemental Table 2).
Discussion
In this population-based cohort study including 57,134 
women, self-reported probiotic milk consumption during 
the first half of pregnancy was statistically associated with 
higher incidence of self-reported breastfeeding complica-
tions leading to healthcare consultations during the first 
month after delivery. Furthermore, self-reported probiotic 
milk consumption was associated with lower prevalence of 
breastfeeding cessation before the baby reached the age of 
4 months.
The findings in this study do not support the hypothesis 
that general probiotic milk intake during pregnancy pre-
vents future breastfeeding complications. However, results 
of different sensitivity analyses suggest that the asso-
ciation between probiotic milk intake and breastfeeding 
Table 1  (continued)
Probiotic milk consumption p  value1 Mean (SD) daily probiotics intake among 
probiotics consumers, ml/day
p  value1
No, number (%) Yes, number (%)
Tertiles of daily non-probiotic yoghurt intake
 1st 13,958 (38.5) 4967 (23.8)  < 0.001 120 (175)  < 0.001
 2nd 11,389 (31.4) 8013 (38.3) 105 (157)
 3rd 10,886 (30.0) 7921 (37.9) 143 (191)
Caesarean section
 No 31,497 (86.9) 18,255 (87.3) 0.16 122 (175) 0.10
 Yes 4736 (13.1) 2646 (12.7) 130 (181)
NICU admission
no 31,948 (88.2) 18,134 (86.8)  < 0.001 123 (174) 0.53
yes 4285 (11.8) 2767 (13.2) 122 (185)
Baby SGA
 No 35,727 (98.6) 20,593 (98.5) 0.46 123 (175) 0.50
 Yes 506 (1.4) 308 (1.5) 141 (224)
Baby LGA
 No 34,772 (96.0) 20,234 (96.8)  < 0.001 123 (176) 0.55
 Yes 1461 (4.0) 667 (3.2) 120 (159)
IQR interquartile range, SGA small for gestational age, according to Marsál, LGA large for gestational age, according to Marsál [24]
1 p value according to Pearson’s chi-square test or two-sided Fisher’s exact test, as appropriate
2 p value according to Kruskal–Wallis test
Table 2  Associations between probiotic milk intake and breastfeeding complications and breastfeeding duration, n = 57,134 women
a Logistic regression adjusted for maternal age, maternal pre-pregnancy BMI, maternal education, family income, maternal smoking, fibre intake, 
energy intake, non-probiotic yoghurt consumption, and non-probiotic milk consumption
Among non-consumers Among probiotic 
milk consumers
Unadjusted Adjusteda
Number (%) Number (%) OR (CI) p OR (CI) p
Mastitis 2,818 (7.8) 1,857 (8.9) 1.16 (1.09–1.23)  < 0.001 1.09 (1.02–1.16) 0.01
Medication for mastitis 1,892 (5.2) 1,235 (5.9) 1.14 (1.06–1.23) 0.001 1.07 (1.00–1.15) 0.09
Sore nipples 2,029 (5.6) 1,566 (7.5) 1.37 (1.28–1.46)  < 0.001 1.22 (1.14–1.31)  < 0.001
Other breastfeeding problems 2,053 (5.7) 1,612 (7.7) 1.39 (1.30–1.49)  < 0.001 1.22 (1.13–1.30)  < 0.001
Any breastfeeding problems 5,154 (14.2) 3,634 (17.4) 1.27 (1.21–1.33)  < 0.001 1.19 (1.10–1.21)  < 0.001
Cessation of predominant 
breastfeeding before 4 months
14,466 (39.9) 7,769 (37.2) 0.89 (0.86–0.92)  < 0.001 0.95 (0.91–0.96) 0.006
Cessation of any breastfeeding 
before 4 months
4,758 (13.1) 1,809 (8.7) 0.63 (0.59–0.66)  < 0.001 0.79 (0.75–0.84)  < 0.001
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complications and duration might not be causal. First, no 
dose–response relationship between the amount of ingested 
probiotics and breastfeeding complications was found. Sec-
ond, probiotics consumers breastfed longer despite increased 
incidence of reported breastfeeding complications. As in 
other studies [2, 25, 26], breastfeeding complications such 
as mastitis were associated with precocious weaning in this 
study population. Third, results seem to be confounded by 
socioeconomic factors such as education. Educated women 
reported a higher probiotic milk intake and are known to 
breastfeed longer [27]. At the same time, educated women 
have higher health literacy, defined as the capacity to obtain, 
process, and understand basic health information and ser-
vices needed to make appropriate health decisions. They are, 
therefore, more observant and consult the health-care system 
more often [28, 29]. This might partly explain the higher 
prevalence of reported breastfeeding problems leading to 
healthcare consultations among probiotic milk consumers 
found in this study. However, results remained significant 
after adjustment for socioeconomic factors, as well as in 
stratified analysis for education, income, and BMI (results 
not shown).
This epidemiologic study underlines the need to perform 
RCTs with defined amounts of specified probiotic strains and 
clinical examination of the women.
While probiotic strains studied in this cohort were La-5, 
Bb12, and LGG, the RCTs previously performed investi-
gated the effect of Lactobacillus (L.) salivarius, L. gasseri, 
and/or L. fermentum. A recently published study showed 
that a daily consumption of 250 ml product A as used in this 
study led to the presence of La-5, Bb12, and LGG in breast 
milk samples for only a small number of women [30]. If the 
positive effects of probiotics on breast health indeed should 
be accomplished by suggested local effects such as com-
petitive exclusion [10], production of antimicrobials [11], 
normalization of breast tissue permeability [12], or increase 
of immunoglobulin A in breast milk epithelium [13], pro-
biotic strains used in these commonly sold probiotic milk 
products might not be effective in regard to breastfeeding 
complications. However, another hypothesis links the risk 
for mastitis to the state of the host’s immune system [4]. 
Several RCTs based on product A were performed showing 
that intake of 250 ml product A/day during pregnancy and 
breastfeeding compared to a placebo fermented milk led to 
a higher prevalence of all three probiotic bacteria strains at 
3 month postpartum in the mothers’ stool samples. Their 
children had a higher prevalence of LGG in their stool sam-
ples at 10 days and 3 months of age [31] and lower risk for 
atopic dermatitis at age 2 years [32]. Another RCT showed 
that ingestion of 250 ml/day of product A reduced the risk 
for antibiotic-associated diarrhoea [33]. Consumption of the 
probiotic milk consumed in this study might thus have an 
impact on the general immune state.
In 2008, Jiménez et al. randomized women (n = 20) with 
remaining mastitis symptoms after antibiotic treatment to 
intake of either L. salivarius and L. gasseri or placebo [7]. 
In 2010, Arroyo et al. randomized women (n = 352) with 
mastitis into three treatment groups: standard antibiotics, L. 
fermentum, or L. salivarius [6]. In both studies, the Lactoba-
cilli groups had lower Staphylococcus counts after treatment 
and improved faster. Another RCT by the same group, pub-
lished in 2016, evaluated a preventive effect of L. salivarius 
intake from pregnancy week 30 until delivery in women 
(n = 108) with a history of mastitis [8]. The probiotics group 
had a significantly lower incidence of mastitis and lower 
bacterial counts if mastitis did occur. In 2017, Hurtado et al. 
randomized women who were given antibiotic treatment at 
delivery (n = 625) to either intake of L. fermentum or pla-
cebo for 16 weeks. Women in the probiotic group had sig-
nificantly lower incidence of mastitis [9]. Furthermore, this 
Table 3  Association between breastfeeding problems and cessation of predominant breastfeeding before 4 months, n = 57,134 women
a Logistic regression adjusted for maternal age, maternal pre-pregnancy BMI, maternal education, family income, maternal smoking, fibre intake, 
and energy intake
Predominant breast-
feeding before age 
4 months (in %) in 
case of breastfeeding 
complication
Unadjusted Adjusteda
Not present Present OR (CI) for cessation of breast-
feeding in case of breastfeeding 
complication
p OR (CI) for cessation of breast-
feeding in case of breastfeeding 
complication
p
Mastitis 61.8 53.3 1.41 (1.33–1.50)  < 0.001 1.47 (1.38–1.57)  < 0.001
Medication for mastitis 61.6 52.8 1.43 (1.33–1.54)  < 0.001 1.50 (1.39–1.61)  < 0.001
Sore nipples 61.8 49.8 1.63 (1.53–1.75)  < 0.001 1.61 (1.50–1.73)  < 0.001
Other breastfeeding problems 63.0 33.6 3.36 (3.13–3.61)  < 0.001 3.22 (3.00–3.46)  < 0.001
Any breastfeeding problems 63.3 48.6 1.83 (1.75–1.91)  < 0.001 1.83 (1.74–1.92)  < 0.001
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study differs by evaluating dietary intake during the first half 
of pregnancy even if it is assumed that the reported habitual 
intake of probiotic milk products in pregnancy is a proxy of 
the continued habitual intake during breastfeeding [16, 34]. 
In this epidemiologic setting, the outcome variables were 
based on the women’s self-reported data and their own ini-
tiative to use health-care services and not on medical records 
with International Classification of Disease (ICD) codes or 
examination performed by health-care professionals, which 
might have introduced bias as described above regarding 
level of education. Incidences of mastitis diagnosis and indi-
cations for antibiotic treatment differ considerably between 
different countries [1, 35], which further impedes compari-
son of study results from different countries. Another RCT 
on 8 week prophylactic L. fermentum intake is currently 
performed in Australia (n = 600) with a reported mastitis 
incidence of 15–21% comparable to the incidence in this 
population [36].
Strengths and limitations
To the best of our knowledge, this is the first study to exam-
ine the possible effect of probiotic milk intake during preg-
nancy on breastfeeding complications and duration in an 
epidemiologic population-based setting. Strengths of this 
study are its size, with 57,134 women included, the com-
prehensive information on lifestyle and socioeconomics and 
the prospective design with registration of probiotic milk 
intake before possible breastfeeding complications might 
occur. The MoBa FFQ has been extensively validated [22, 
37, 38]. However, several limitations need to be considered 
when interpreting the results. The outcome was based on 
the women’s self-reported data referring to if and why they 
contacted health-care services. As discussed above, this 
might have introduced bias, as better educated women are 
known to both breastfeed longer and having a lower thresh-
old for contacting health-care services [28]. Even if a clini-
cal follow-up of all women would have been desirable, it 
is unfeasible in a population-based study like MoBa. Since 
exposure is self-reported in a semi-quantitative FFQ, there 
is no information on the exact intake of probiotic bacterial 
count or measurement of actual bacterial count and type in 
the breast milk. However, the reported median daily intake 
in this study is comparable to the reported intake in most of 
the published RCTs [6-8]. The FFQ is answered at gesta-
tional week 22 and there is no comparable information on 
probiotics intake after delivery. However, it can be assumed 
that the reported habitual intake of probiotic milk products 
in pregnancy is a proxy of the continued habitual intake dur-
ing breastfeeding. Although pregnancy is a time when most 
women think a lot about healthy eating, the major changes 
occur for intake of alcohol and coffee, while their core diet 
largely remains unchanged [34]. Maternal probiotic milk 
intake was also asked for in a less comprehensive way in 
MoBa Q1 and Q3 regarding the time period from before 
pregnancy to answering Q3 in pregnancy week 32, show-
ing that most women continued to consume probiotic milk 
products as before pregnancy [16].
Administration of antibiotics, common as prophylaxis 
in obstetrics, or as treatment for manifest infection, might 
have interfered with the probiotic effect; this type of datum 
is not available in the MoBa data set. However, stratifying 
women by vaginal delivery or delivery by caesarean section, 
when prophylactic antibiotics treatment is usually given, 
did not change the results (data not shown). Unfortunately, 
MoBa provides no data on the exact time when the mother 
attracts breastfeeding complications or stops breastfeeding. 
Therefore, the possibility of reverse causality explaining the 
results—women breastfeeding longer having more time at 
risk for breastfeeding complications—cannot be completely 
excluded. However, as the analysis was restricted to women 
who initiated breastfeeding as well as to breastfeeding com-
plications reported during the first month after delivery, we 
judge the risk for reverse causality as very low. Women were 
asked what, but not how, they fed their children; whether 
they were breastfeeding and/or bottle-feeding pumped breast 
milk might have affected the risk of developing breastfeed-
ing complications. Despite adjustment for relevant con-
founders, residual confounding is probably still part of this 
association, as discussed above.
Conclusions
Among 57,134 women from MoBa, self-reported probiotic 
milk intake during the first half of pregnancy was statisti-
cally associated with increased risk for self-reported breast-
feeding complications, including mastitis. However, this 
association is probably not causal, as probiotic milk intake 
was also associated with longer breastfeeding duration. Fur-
ther studies, specifically large RCTs with specified probiotic 
strains, defined exposure time, and clinical evaluation of 
breast complications in different populations, are needed to 
further investigate the association between probiotics intake 
and breastfeeding complications.
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